Castle Biosciences, Inc. (CSTL) reported second-quarter 2026 revenue of $103.5 million, topping the consensus estimate of $88.0 million and rising 20.1% from a year earlier. Gross profit came in at $79.8 million, up 16.5% year over year, reflecting continued top-line growth.
Profitability remained under pressure, with operating loss narrowing to $3.1 million. Net loss attributable to common shareholders was $2.1 million, compared with a smaller loss a year ago, and diluted loss per share was $0.07 versus expectations for a larger loss.
Cash flow and balance sheet figures showed a solid liquidity position:
Following the release, the stock rose 6.31% after the market close.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Castle Biosciences, Inc. Insider Trading Activity
Castle Biosciences, Inc. insiders have traded $CSTL stock on the open market 95 times in the past 6 months. Of those trades, 0 have been purchases and 95 have been sales.
Here’s a breakdown of recent trading of $CSTL stock by insiders over the last 6 months:
- DEREK J MAETZOLD (Pres. & Chief Exec. Officer) has made 0 purchases and 86 sales selling 148,589 shares for an estimated $3,784,068.
- TOBIN W JUVENAL (Chief Commercial Officer) sold 20,863 shares for an estimated $526,582
- KRISTEN M OELSCHLAGER (Chief Operating Officer) has made 0 purchases and 3 sales selling 17,173 shares for an estimated $387,487.
- FRANK STOKES (Chief Financial Officer) has made 0 purchases and 3 sales selling 13,001 shares for an estimated $359,980.
- G BRADLEY COLE has made 0 purchases and 2 sales selling 7,403 shares for an estimated $210,727.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Castle Biosciences, Inc. Hedge Fund Activity
We have seen 94 institutional investors add shares of Castle Biosciences, Inc. stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP added 643,098 shares (+30.4%) to their portfolio in Q1 2026, for an estimated $15,788,055
- PORTOLAN CAPITAL MANAGEMENT, LLC removed 379,180 shares (-21.9%) from their portfolio in Q1 2026, for an estimated $9,308,869
- QUBE RESEARCH & TECHNOLOGIES LTD added 324,065 shares (+137.6%) to their portfolio in Q1 2026, for an estimated $7,955,795
- CITADEL ADVISORS LLC removed 245,379 shares (-67.0%) from their portfolio in Q1 2026, for an estimated $6,024,054
- MORGAN STANLEY added 225,357 shares (+110.7%) to their portfolio in Q1 2026, for an estimated $5,532,514
- SG AMERICAS SECURITIES, LLC added 223,624 shares (+1051.8%) to their portfolio in Q1 2026, for an estimated $5,489,969
- WELLINGTON MANAGEMENT GROUP LLP removed 218,560 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $5,365,648
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Castle Biosciences, Inc. Analyst Ratings
Wall Street analysts have issued reports on $CSTL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 05/13/2026
To track analyst ratings and price targets for Castle Biosciences, Inc., check out Quiver Quantitative's $CSTL forecast page.
Castle Biosciences, Inc. Price Targets
Multiple analysts have issued price targets for $CSTL recently. We have seen 4 analysts offer price targets for $CSTL in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Max Masucci from Roth Capital set a target price of $40.0 on 06/25/2026
- Mark Massaro from BTIG set a target price of $40.0 on 05/13/2026
- Catherine Ramsey from Baird set a target price of $43.0 on 05/07/2026
- Kyle Mikson from Canaccord Genuity set a target price of $40.0 on 04/20/2026
